- Home
- GORO vs CYCC Comparison
GORO vs CYCC Comparison
Compare GORO & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORO
- CYCC
- Stock Information
- Founded
- GORO 1998
- CYCC 1992
- Country
- GORO United States
- CYCC Malaysia
- Employees
- GORO N/A
- CYCC N/A
- Industry
- GORO Precious Metals
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- GORO Basic Materials
- CYCC Health Care
- Exchange
- GORO Nasdaq
- CYCC Nasdaq
- Market Cap
- GORO 49.9M
- CYCC 47.6M
- IPO Year
- GORO N/A
- CYCC N/A
- Fundamental
- Price
- GORO $0.56
- CYCC $0.25
- Analyst Decision
- GORO Strong Buy
- CYCC Strong Buy
- Analyst Count
- GORO 1
- CYCC 1
- Target Price
- GORO $1.25
- CYCC $11.00
- AVG Volume (30 Days)
- GORO 3.7M
- CYCC 7.3M
- Earning Date
- GORO 05-20-2025
- CYCC 05-20-2025
- Dividend Yield
- GORO N/A
- CYCC 59.13%
- EPS Growth
- GORO N/A
- CYCC N/A
- EPS
- GORO N/A
- CYCC N/A
- Revenue
- GORO $65,726,000.00
- CYCC $43,000.00
- Revenue This Year
- GORO $68.69
- CYCC $137.21
- Revenue Next Year
- GORO $19.92
- CYCC N/A
- P/E Ratio
- GORO N/A
- CYCC N/A
- Revenue Growth
- GORO N/A
- CYCC N/A
- 52 Week Low
- GORO $0.12
- CYCC $0.17
- 52 Week High
- GORO $0.74
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- GORO 56.48
- CYCC 47.06
- Support Level
- GORO $0.58
- CYCC $0.28
- Resistance Level
- GORO $0.64
- CYCC $0.37
- Average True Range (ATR)
- GORO 0.06
- CYCC 0.07
- MACD
- GORO 0.01
- CYCC 0.01
- Stochastic Oscillator
- GORO 66.94
- CYCC 20.67
About GORO Gold Resource Corporation
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.